EyePoint, Inc. (EYPT)
0.44
-2.55
(-85.28%)
USD |
NASDAQ |
Oct 19, 16:00
0.4389
0.00 (0.00%)
After-Hours: 16:48
EyePoint Cash from Operations (Annual) : -240.11M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -240.11M |
| December 31, 2024 | -126.23M |
| December 31, 2023 | 1.875M |
| December 31, 2022 | -65.00M |
| December 31, 2021 | -50.10M |
| December 31, 2020 | -14.44M |
| December 31, 2019 | -56.70M |
| December 31, 2018 | -22.59M |
| June 30, 2017 | -20.49M |
| June 30, 2016 | -16.32M |
| Date | Value |
|---|---|
| June 30, 2015 | 10.30M |
| June 30, 2014 | -10.67M |
| June 30, 2013 | -8.745M |
| June 30, 2012 | -9.001M |
| June 30, 2011 | -3.17M |
| June 30, 2010 | 9.899M |
| June 30, 2009 | -8.436M |
| June 30, 2008 | -5.143M |
| June 30, 2007 | -21.35M |
| June 30, 2006 | -16.21M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Ocular Therapeutix, Inc. | -204.88M |
| Corcept Therapeutics, Inc. | 142.00M |
| Eli Lilly & Co. | 16.81B |
| Regeneron Pharmaceuticals, Inc. | 4.979B |
| Nuvation Bio, Inc. | -173.43M |